Immunovant, Inc. IMVT Payments Of Stock Issuance Costs
Payments Of Stock Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s payments of stock issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s payments of stock issuance costs?
- Immunovant, Inc. (IMVT) reported payments of stock issuance costs of $126K in Q1 2026.
- How has Immunovant, Inc.'s payments of stock issuance costs changed year-over-year?
- Immunovant, Inc.'s payments of stock issuance costs decreased by 60.5% year-over-year, from $319K to $126K.
- What does payments of stock issuance costs mean?
- This metric represents the direct cash costs incurred in connection with the issuance of equity securities, such as legal, accounting, and underwriting fees. These costs are typically deducted from the gross proceeds of a capital raise and reflect the friction costs of accessing public or private equity markets. High or increasing costs may indicate complex regulatory or marketing requirements for capital formation.